January 14, 2020
iBio (NYSE American:IBIO) is continuing its transition from a licensing business to a manufacturing services provider and developer of proprietary biologics. Central to the initiative is a new brand for its core technology in 2019, the FastPharming ...
Continue ReadingDecember 9, 2019
There is a chronic shortage of organs available for transplant. Bioprinted organs could dramatically increase accessibility to all patients in need of transplants. Some simpler biofabricated tissues are already entering the clinic, with the promise of ...
Continue ReadingOctober 9, 2019
Post-translational modification is a critical step in the synthesis of biotherapeutic molecules. Among these alterations to the original naked protein, glycosylation may be the most significant and difficult to properly complete. In this roundtable, we ...
Continue ReadingJuly 25, 2019
iBio has expanded its CDMO service offerings to include independent sterile liquid cGMP fill-finish services to support the preclinical and clinical trial needs of drug developers. This new service complements iBio’s existing biologics bulk drug ...
Continue ReadingMay 30, 2019
iBio offers development and manufacturing services for biologic drug substances and drug products, built around our proprietary plant-based platform technology. Client support is offered from early development through fill and finish for research-grade, ...
Continue Reading